Jacek Wachowiak

Jacek Wachowiak

Auto-generated profile, based on publicly available information

Jacek Wachowiak

Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60-572 Poznan, Poland

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2017 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
SCS Corbacioglu
S Corbacioglu
ECE Carreras
E Carreras
MAM Ansari
M Ansari
ABA Balduzzi
A Balduzzi
Simone CesaroSimone Cesaro
Simone Cesaro
PBP Bader
P Bader
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of HCT that belongs to a group of diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe SOS/VOD results in multi-organ dysfunction/failure with a mortality rate >80%. A timely diagnosis of SOS/VOD is of critical importance, given the availability of therapeutic options with favorable tolerability. Current diagnostic criteria are used for adults and children. However, over the last decade it has become clear that SOS/VOD is significantly different between the age groups in terms of incidence, genetic predisposition, clinical presentation, prevention, treatment and outcome. Improved understanding of SOS/VOD and the availability of effective treatment questions the use of the Baltimore and Seattle criteria for diagnosing SOS/VOD in children. The aim of this position paper is to propose new diagnostic and severity criteria for SOS/VOD in children on behalf of the European Society for Blood and Marrow Transplantation.

1 January 2008 in Blood
Verified
Journal Article
Closed access
PDF file
HOHulya Ozsahin
Hulya Ozsahin
MCMarina Cavazzana
Marina Cavazzana
LNLuigi D. Notarangelo
Luigi D. Notarangelo
ASAnsgar Schulz
Ansgar Schulz
ATAdrian J. Thrasher
Adrian J. Thrasher
AFAlain Fischer
Alain Fischer
Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency with microthrombocytopenia, eczema, recurrent infections, autoimmune disorders, and malignancies that are life-threatening in the majority of patients. In this long-term, retrospective, multicenter study, we analyzed events that occurred in 96 WAS patients who received transplants between 1979 and 2001 who survived at least 2 years following hematopoietic stem-cell transplantation (HSCT). Events included chronic graft-versus-host disease (cGVHD), autoimmunity, infections, and sequelae of before or after HSCT complications. Three patients (3%) died 2.1 to 21 years following HSCT. Overall 7-year event-free survival rate was 75%. It was lower in recipients of mismatched related donors, also in relation with an older age at HSCT and disease severity. The most striking finding was the observation of cGVHD-independent autoimmunity in 20% of patients strongly associated with a mixed/split chimerism status (P < .001), suggesting that residual-host lymphocytes can mediate autoimmune disease despite the coexistence of donor lymphocytes. Infectious complications (6%) related to splenectomy were also significant and may warrant a more restrictive approach to performing splenectomy in WAS patients. Overall, this study provides the basis for a prospective, standardized, and more in-depth detailed analysis of chimerism and events in long-term follow-up of WAS patients who receive transplants to design better-adapted therapeutic strategies.

21 July 2016 in Blood
Verified
Journal Article
Open access
PDF file
BMBeatriz Morillo-Gutierrez
Beatriz Morillo-Gutierrez
RBRita Beier
Rita Beier
KRKanchan Rao
Kanchan Rao
LBLauri Burroughs
Lauri Burroughs
ASAnsgar Schulz
Ansgar Schulz
MSMary Slatter
Mary Slatter
Key Points: Treosulfan, a low-toxicity alkylating agent, can be used effectively as part of conditioning for HSCT in children with CGD. Long-term follow-up is required to ascertain effects, particularly on gonadal function and compare with other regimens.

8 June 2015 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
RLR Peffault de Latour
R Peffault de Latour
CPChristina Peters
Christina Peters
BGB Gibson
B Gibson
BSB Strahm
B Strahm
ALA Lankester
A Lankester
O(on behalf of the Pediatric Working Party (PDWP) and the Severe Aplastic Anemia Working Party (SAAWP) of the European Group for Blood and Marrow Transplantation (EBMT)
on behalf of the Pediatric Working Party (PDWP) and the Severe Aplastic Anemia Working Party (SAAWP) of the European Group for Blood and Marrow Transplantation (EBMT)

22 March 2012 in Blood
Verified
Journal Article
Closed access
PDF file
JSJan Styczyński
Jan Styczyński
ABAdriana Balduzzi
Adriana Balduzzi
LGLidia Gil
Lidia Gil
MLMyriam Labopin
Myriam Labopin
RHRose-Marie Hamladji
Rose-Marie Hamladji
CPChristina Peters
Christina Peters
We investigated prospectively factors influencing the safety of hematopoietic stem cell (HSC) collection in 453 pediatric donors. The children in the study donated either BM or peripheral blood stem cells (PBSCs) according to center policy. A large variability in approach to donor issues was observed between the participating centers. Significant differences were observed between BM and PBSC donors regarding pain, blood allotransfusion, duration of hospital stay, and iron supplementation; however, differences between the groups undergoing BM vs PBSC donation preclude direct risk comparisons between the 2 procedures. The most common adverse event was pain, reported mainly by older children after BM harvest, but also observed after central venous catheter (CVC) placement for PBSC collection. With regard to severe adverse events, one patient (0.7%) developed a pneumothorax with hydrothorax after CVC placement for PBSC collection. The risk of allotransfusion after BM harvest was associated with a donor age of < 4 years and a BM harvest volume of > 20 mL/kg. Children < 4 years were at higher risk than older children for allotransfusion after BM harvest and there was a higher risk of complications from CVC placement before apheresis. We conclude that PBSC and BM collection are safe procedures in children.

1 February 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JSJan Styczyński
Jan Styczyński
KCKrzysztof Czyzewski
Krzysztof Czyzewski
MWM Wysocki
M Wysocki
OGOlga Gryniewicz-Kwiatkowska
Olga Gryniewicz-Kwiatkowska
AKA Kolodziejczyk-Gietka
A Kolodziejczyk-Gietka
PHPolish Society Of Paediatric Oncology And Haematology
Polish Society Of Paediatric Oncology And Haematology